Heparin natriya (When ATH C05BA03)

When ATH:
C05BA03

Characteristic

Get out of the lungs of cattle. Amorphous white powder with a yellowish tinge, without smell. Soluble in water and saline, pH 1% Water 6-7.5 solution. Active biological method to determine the ability of lengthening the clotting time of blood and expressed in units of.

Pharmacological action

Antykoahulyantnoe.

Application

Unstable angina, acute myocardial infarction; thromboembolic complications of myocardial infarction, operations on the heart and blood vessels, pulmonary and cerebral vessels, thrombophlebitis (Prevention and treatment); DIC, microthrombogenesis prevention and microcirculation disturbances; thrombosis of renal vein; hemolytic uremic syndrome; atrial fibrillation, mitral heart defects (prevention of thrombotic events); bacterial endocarditis; glomerulonephritis; lupus nephritis; rheumatism; bronchial asthma; extracorporeal methods (cardiopulmonary bypass during heart surgery, hemosorption, hemodialysis, pyeritonyealinyi dialysis, tsytaferez), forced diuresis; washing venous catheters.

Contraindications

Gyemorragichyeskii diatyez, leukemia, anemia, increased vascular permeability, Polyps, malignancies and ulcerative lesions GIT, severe liver and kidney, brain surgery and spinal.

Pregnancy and breast-feeding

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Side effects

Dizziness, headache, nausea, anorexia, vomiting, diarrhea, alopecia; early (2-4 Days of treatment) and later (Autoimmune) thrombocytopenia; hemorrhagic complications is bleeding in the digestive tract or urinary tract, retroperitoneal bleeding in the ovaries, adrenal (with the development of acute adrenal insufficiency), osteoporosis, calcification of soft tissues, inhibition of the synthesis of aldosterone, elevated transaminase levels in the blood, allergic reactions (fever, rashes, bronchial asthma, anaphylactoid reactions), Local irritation, hematoma, pain when administered.

Cooperation

Efficiency is enhanced with acetylsalicylic acid, dekstranom, Tetracycline, phenylbutazone, ibuprofen, Indomethacin, varfarinom, dikumarinom (the risk of bleeding), weakened-cardiac glycosides, antihistamines, ethacrynic acid, changes — Nicotinic Acid.

Dosing and Administration

P / (deep in the subcutaneous fat, changing injection sites), I / (slowly), / m, inhalation -on 20-50 thousand. U/d, depending on the evidence; w / w loading dose is typically administered 5 th. ED, and then by 20-40 thousand. U/d using infusion pump (use constant or intermittent circuit introduction — on 5-10 thousand. U every 4-6 h); to prevent postoperative thrombosis in/in introducing small doses — 17 th. IU/day for 3-5 days; for the prevention tromboamboliy s/to- 5 th. U 2-8 h before surgery, then every 8 h the same dose administered during the 7 days; to improve microcirculation introducing p/to-an average of 2.5-5th. U 3-4 times a day for 5-7 days, with a gradual decrease in dose.

Precautions

Requires constant monitoring of blood clotting time; cancellation should be done gradually.

Cooperation

Active substance	Description of interaction
Acrivastine	FMR: antagonizm. Reduces effect.
Acetylsalicylic acid	FMR: synergism. It increases the risk of hemorrhagic complications.
Benzathines benzilpenicillin	FMR. Do effect.
Warfarin	FMR: synergism. Strengthens (mutually) effect, It increases the risk of bleeding.
Gidroksixloroxin	FMR. It increases the chance of bleeding.
Gidroxlorotiazid + Captopril	FMR. Against the background of heparin increases the likelihood of developing "kaptoprilovoy" hyperkalemia.
Dextran	FMR: synergism. It increases the risk of bleeding.
Digoxin	FMR: antagonizm. Weakens effect.
Diclofenac	FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution.
Diclofenac potassium	FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution.
Dipiridamol	FMR: synergism. Increases (mutually) effect and the risk of hemorrhagic complications.
Doxycycline	FMR: antagonizm. Weakens effect.
Ibuprofen	FMR: synergism. It increases the risk of hemorrhagic complications.
Indomethacin	FMR: synergism. It increases the risk of hemorrhagic complications.
Ketoprofen	FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution.
Ketorolac	FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution.
Clopidogrel	FMR: synergism. Increases (mutually) effect and the risk of hemorrhagic complications.
Loratadine	FMR: antagonizm. Reduces effect.
Meloxicam	FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution.
Naproxen	FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution.
A nicotinic acid	FMR. Can change effect.
Piroxicam	FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution.
Promethazine	FMR: antagonizm. Weakens effect.
Fexofenadine	FMR: antagonizm. Weakens effect.
Phenylbutazone	FMR: synergism. It increases the risk of hemorrhagic complications.
Flurbyprofen	FMR: synergism. It increases the risk of hemorrhagic complications; joint application requires caution.
Cetirizine	FMR: antagonizm. Weakens effect.
Ciprogeptadin	FMR: antagonizm. Reduces effect.
Ethacrynic acid	FMR: antagonizm. Reduces effect.